RMTI RSI Chart
Last 7 days
6.7%
Last 30 days
18.2%
Last 90 days
29.6%
Trailing 12 Months
-25.8%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 86.6M | 0 | 0 | 0 |
2023 | 76.4M | 75.8M | 80.8M | 83.6M |
2022 | 62.6M | 66.1M | 68.8M | 72.8M |
2021 | 61.8M | 61.1M | 61.8M | 61.9M |
2020 | 61.6M | 62.7M | 62.5M | 62.2M |
2019 | 64.0M | 63.9M | 62.7M | 61.3M |
2018 | 57.7M | 59.3M | 61.4M | 63.4M |
2017 | 54.2M | 54.0M | 55.9M | 57.3M |
2016 | 55.1M | 55.6M | 54.0M | 53.3M |
2015 | 55.1M | 55.0M | 55.7M | 55.4M |
2014 | 53.0M | 53.1M | 53.7M | 54.2M |
2013 | 50.2M | 51.0M | 51.4M | 52.4M |
2012 | 47.7M | 48.0M | 48.7M | 49.8M |
2011 | 57.9M | 54.2M | 51.4M | 49.0M |
2010 | 0 | 56.3M | 57.9M | 59.6M |
2009 | 0 | 0 | 0 | 54.7M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 17, 2024 | timmins megan c. | sold (taxes) | -4,391 | 1.4 | -3,137 | evp, clo and secretary |
Mar 17, 2024 | strobeck mark | sold (taxes) | -8,541 | 1.4 | -6,101 | president and ceo |
Mar 14, 2024 | neri jesse | acquired | - | - | 33,330 | svp, finance |
Mar 14, 2024 | timmins megan c. | acquired | - | - | 50,000 | evp, clo and secretary |
Mar 14, 2024 | strobeck mark | acquired | - | - | 100,000 | president and ceo |
Oct 16, 2023 | lau joan | acquired | - | - | 25,000 | - |
May 23, 2023 | radie robert s | acquired | - | - | 24,715 | - |
May 23, 2023 | nissenson allen | acquired | - | - | 24,715 | - |
May 23, 2023 | smiley andrea heslin | acquired | - | - | 24,715 | - |
Which funds bought or sold RMTI recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | COMERICA BANK | unchanged | - | -37.00 | 271 | -% |
May 16, 2024 | JANE STREET GROUP, LLC | sold off | -100 | -61,007 | - | -% |
May 15, 2024 | CITADEL ADVISORS LLC | added | 139 | 49,561 | 94,620 | -% |
May 15, 2024 | STATE STREET CORP | unchanged | - | -17,090 | 123,345 | -% |
May 15, 2024 | Royal Bank of Canada | reduced | -74.78 | - | - | -% |
May 15, 2024 | TWO SIGMA INVESTMENTS, LP | sold off | -100 | -90,215 | - | -% |
May 15, 2024 | MARSHALL WACE, LLP | reduced | -44.13 | -168,537 | 162,395 | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | added | 72.61 | 2,621 | 7,699 | -% |
May 15, 2024 | Cetera Advisor Networks LLC | unchanged | - | -3,249 | 23,451 | -% |
May 15, 2024 | ARMISTICE CAPITAL, LLC | added | 41.99 | 864,922 | 4,365,200 | 0.06% |
Unveiling Rockwell Medical Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Rockwell Medical Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
JNJ | 372.2B | 85.6B | 9.67 | 4.35 | ||||
MRK | 332.3B | 61.4B | 144.1 | 5.41 | ||||
AMGN | 167.7B | 29.5B | 44.55 | 5.68 | ||||
PFE | 162.3B | 57.8B | 129.52 | 2.81 | ||||
GILD | 84.4B | 27.4B | 174.21 | 3.07 | ||||
TEVA | 18.4B | 16.0B | -37.29 | 1.15 | ||||
MID-CAP | ||||||||
ALKS | 4.1B | 1.7B | 9.41 | 2.37 | ||||
PRGO | 4.1B | 4.6B | -528.11 | 0.89 | ||||
BHC | 2.5B | 9.0B | -5.45 | 0.28 | ||||
AMPH | 2.1B | 676.2M | 13.75 | 3.14 | ||||
SMALL-CAP | ||||||||
TLRY | 1.5B | 743.2M | -4.35 | 2.06 | ||||
TXMD | 25.8M | 1.3M | -3.49 | 19.84 | ||||
ACRX | 18.4M | 89.6M | -1.29 | 0.19 | ||||
AGRX | 2.5M | 21.5M | -0.32 | 0.12 | ||||
ACOR | 633.5K | 115.7M | 0 | 0.01 |
Rockwell Medical Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | 2.6% | 22,676,000 | 22,093,000 | 23,771,000 | 18,080,000 | 19,668,000 | 19,313,000 | 18,691,000 | 18,682,000 | 16,124,000 | 15,332,500 | 15,988,000 | 15,137,000 | 15,473,000 | 15,164,000 | 15,280,000 | 15,896,000 | 15,857,000 | 15,491,000 | 15,407,000 | 14,846,000 | 15,559,000 |
Gross Profit | 6.8% | 3,064,000 | 2,870,000 | 2,202,000 | 1,033,000 | 2,599,000 | 2,340,500 | 777,000 | 1,745,000 | -786,000 | -2,230,500 | -329,000 | -262,000 | 401,000 | 385,000 | 346,000 | 881,000 | 1,113,000 | 1,112,230 | -17,000 | 733,149 | 1,010,392 |
S&GA Expenses | 9.8% | 594,000 | 541,000 | 556,000 | 530,000 | 498,000 | 351,000 | 762,000 | 526,000 | 455,000 | 873,000 | 1,541,000 | 1,468,000 | 1,851,000 | 2,132,500 | 1,669,000 | 1,997,000 | 2,073,000 | 1,901,313 | 1,827,000 | 2,218,997 | 3,102,378 |
R&D Expenses | - | 18,000 | - | 494,000 | 167,000 | 278,000 | - | 469,000 | 926,000 | 1,567,000 | - | 1,221,000 | 2,416,000 | 1,809,000 | - | 1,745,000 | 1,616,000 | 1,822,000 | - | 1,475,000 | 2,958,276 | 497,276 |
EBITDA Margin | 5.2% | -0.27 | -0.29 | -0.31 | -0.34 | -0.33 | -0.35 | -0.36 | -0.38 | -0.40 | -0.40 | -0.40 | -0.40 | -0.40 | -0.40 | - | - | - | - | - | - | - |
Interest Expenses | -61.1% | 431,000 | 1,108,000 | 411,000 | 395,000 | 387,000 | 437,000 | 476,000 | 485,000 | 540,000 | 587,500 | 609,000 | 583,000 | 581,000 | 590,000 | 666,000 | 521,000 | 102,000 | 9,000 | 16,000 | - | - |
EBT Margin | 3.5% | -0.32 | -0.33 | -0.34 | -0.37 | -0.36 | -0.38 | -0.40 | -0.42 | -0.44 | -0.45 | -0.45 | -0.45 | -0.45 | -0.45 | - | - | - | - | - | - | - |
Net Income | -14.5% | -1,731,000 | -1,512,000 | -1,872,000 | -3,305,000 | -1,750,000 | -2,361,000 | -4,190,000 | -4,967,000 | -7,162,000 | -8,941,000 | -7,581,000 | -8,400,000 | -7,752,000 | -8,663,000 | -7,350,000 | -6,893,000 | -7,984,000 | -7,302,000 | -7,855,000 | -10,292,000 | -8,679,000 |
Net Income Margin | 3.7% | -0.10 | -0.10 | -0.11 | -0.15 | -0.17 | -0.26 | -0.37 | -0.43 | -0.51 | -0.53 | -0.52 | -0.53 | -0.50 | -0.50 | - | - | - | - | - | - | - |
Free Cashflow | -5481.4% | -2,400,000 | -43,000 | -3,753,000 | -1,716,000 | -3,900,000 | -112,000 | -1,102,000 | -5,904,000 | -9,811,000 | -9,026,000 | -7,075,000 | -4,938,000 | -12,495,000 | -8,569,000 | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -2.8% | 51.00 | 52.00 | 53.00 | 38.00 | 40.00 | 47.00 | 54.00 | 59.00 | 37.00 | 49.00 | 59.00 | 64.00 | 69.00 | 78.00 | 85.00 | 59.00 | 67.00 | 44.00 | 48.00 | 57.00 | 49.00 |
Current Assets | -7.2% | 27.00 | 29.00 | 28.00 | 28.00 | 30.00 | 35.00 | 42.00 | 47.00 | 25.00 | 35.00 | 46.00 | 52.00 | 59.00 | 69.00 | 78.00 | 52.00 | 59.00 | 37.00 | 41.00 | 48.00 | 40.00 |
Cash Equivalents | -26.1% | 7.00 | 9.00 | 8.00 | 9.00 | 11.00 | 10.00 | 13.00 | 31.00 | 10.00 | 13.00 | 23.00 | 32.00 | 36.00 | 49.00 | 57.00 | 27.00 | 37.00 | 12.00 | 14.00 | 21.00 | 21.00 |
Inventory | 3.4% | 6.00 | 6.00 | 5.00 | 6.00 | 6.00 | 6.00 | 5.00 | 5.00 | 6.00 | 4.00 | 4.00 | 5.00 | 4.00 | 4.00 | 4.00 | 5.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
Net PPE | -4.2% | 6.00 | 6.00 | 7.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 3.00 | 3.00 | 2.00 | 3.00 | 3.00 | 2.00 | 2.00 | 2.00 | 3.00 | 3.00 | 3.00 |
Goodwill | 0% | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Liabilities | -2.6% | 30.00 | 31.00 | 31.00 | 29.00 | 28.00 | 33.00 | 38.00 | 39.00 | 42.00 | 46.00 | 48.00 | 45.00 | 43.00 | 44.00 | 43.00 | 42.00 | 45.00 | 24.00 | 24.00 | 27.00 | 29.00 |
Current Liabilities | -10.1% | 15.00 | 17.00 | 21.00 | 17.00 | 15.00 | 18.00 | 19.00 | 19.00 | 20.00 | 21.00 | 22.00 | 34.00 | 11.00 | 13.00 | 13.00 | 11.00 | 13.00 | 12.00 | 12.00 | 15.00 | 16.00 |
Long Term Debt | -0.3% | 8.00 | 8.00 | 3.00 | 5.00 | 6.00 | 8.00 | 9.00 | 10.00 | 12.00 | 13.00 | 14.00 | - | 21.00 | 21.00 | 21.00 | 21.00 | 21.00 | - | - | - | - |
LT Debt, Current | - | - | - | 6.00 | 5.00 | 3.00 | 2.00 | 5.00 | 5.00 | 7.00 | 7.00 | 7.00 | 21.00 | - | - | - | - | - | - | - | - | - |
LT Debt, Non Current | -100.0% | - | 8.00 | 3.00 | 5.00 | 6.00 | 8.00 | 9.00 | 10.00 | 12.00 | 13.00 | 14.00 | - | 21.00 | 21.00 | 21.00 | 21.00 | 21.00 | - | - | - | - |
Shareholder's Equity | -3.0% | 21.00 | 21.00 | 22.00 | 10.00 | 13.00 | 14.00 | 16.00 | 20.00 | - | 3.00 | 11.00 | 18.00 | 26.00 | 34.00 | 42.00 | 16.00 | 22.00 | 20.00 | 24.00 | 30.00 | 20.00 |
Retained Earnings | -0.4% | -398 | -397 | -395 | -393 | -390 | -388 | -386 | -382 | -377 | -370 | -361 | -353 | -345 | -337 | -328 | -321 | -314 | -306 | -299 | -291 | -281 |
Additional Paid-In Capital | 0.3% | 420 | 418 | 417 | 403 | 403 | 403 | 402 | 402 | 372 | 373 | 372 | 372 | 371 | 372 | 371 | 338 | 336 | 327 | 323 | - | - |
Shares Outstanding | 0.7% | 29.00 | 29.00 | 28.00 | 17.00 | 13.00 | 12.00 | 11.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | - | - | - | - | - | - | - |
Float | - | - | - | - | 91.00 | - | - | - | 11.00 | - | - | - | 29.00 | - | - | - | 112 | - | - | - | 153 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -5481.4% | -2,400 | -43.00 | -3,753 | -1,716 | -3,900 | -112 | -1,102 | -5,904 | -9,811 | -9,026 | -7,075 | -4,938 | -12,495 | -8,569 | -4,918 | -9,616 | -6,538 | -5,300 | -6,175 | -10,354 | -5,423 |
Share Based Compensation | 15.1% | 251 | 218 | 212 | 309 | 193 | 220 | 177 | 97.00 | -179 | 385 | 361 | 433 | -236 | 751 | 250 | -1,461 | 935 | 1,057 | 876 | 1,501 | 1,517 |
Cashflow From Investing | -106.9% | -139 | 2,008 | -10,291 | -64.00 | 5,302 | 3,218 | -14,696 | -51.00 | 9,133 | 540 | -1,364 | 1,647 | -512 | 637 | 1,875 | -1,886 | 2,586 | 172 | -1,141 | -7,357 | 3,577 |
Cashflow From Financing | 124.0% | 178 | -742 | 12,845 | -130 | -631 | -5,984 | -2,002 | 26,823 | -2,687 | -1,624 | -549 | -6.00 | - | -1.00 | 32,960 | 800 | 29,557 | 2,502 | 321 | 18,210 | 52.00 |
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Income Statement [Abstract] | ||
Net Sales | $ 22,676 | $ 19,668 |
Cost of Sales | 19,612 | 17,069 |
Gross Profit | 3,064 | 2,599 |
Research and Product Development | 18 | 278 |
Selling and Marketing | 594 | 498 |
General and Administrative | 3,776 | 3,250 |
Operating Loss | (1,324) | (1,427) |
Other Expense: | ||
Interest Expense | (431) | (387) |
Interest Income | 24 | 64 |
Total Other Expense, net | (407) | (323) |
Net Loss | $ (1,731) | $ (1,750) |
Basic Net Loss per Share (in dollars per share) | $ (0.06) | $ (0.10) |
Diluted Net Loss per Share (in dollars per share) | $ (0.06) | $ (0.10) |
Basic Weighted Average Shares Outstanding (in shares) | 29,327,204 | 18,359,940 |
Diluted Weighted Average Shares Outstanding (in shares) | 29,327,204 | 18,359,940 |
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
ASSETS | ||
Cash and Cash Equivalents | $ 6,642 | $ 8,983 |
Investments Available-for-Sale | 1,977 | 1,952 |
Accounts Receivable, net | 11,094 | 10,901 |
Inventory, net | 6,073 | 5,871 |
Prepaid and Other Current Assets | 910 | 1,063 |
Total Current Assets | 26,696 | 28,770 |
Property and Equipment, net | 6,134 | 6,402 |
Inventory, Non-Current | 178 | 178 |
Right of Use Assets - Operating, net | 3,884 | 2,713 |
Right of Use Assets - Financing, net | 1,762 | 1,903 |
Intangible Assets, net | 10,621 | 10,759 |
Goodwill | 921 | 921 |
Other Non-Current Assets | 527 | 527 |
Total Assets | 50,723 | 52,173 |
LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
Accounts Payable | 4,919 | 4,516 |
Accrued Liabilities | 5,253 | 7,149 |
Deferred Consideration - Current | 2,500 | 2,500 |
Lease Liabilities - Operating - Current | 1,464 | 1,381 |
Lease Liabilities - Financing - Current | 566 | 558 |
Deferred License Revenue - Current | 46 | 46 |
Insurance Financing Note Payable | 0 | 244 |
Customer Deposits | 201 | 243 |
Total Current Liabilities | 14,949 | 16,637 |
Lease Liabilities-Operating - Long-Term | 2,504 | 1,433 |
Lease Liabilities-Financing - Long-Term | 1,384 | 1,530 |
Term Loan - Long-Term, net of issuance costs | 8,265 | 8,293 |
Deferred License Revenue - Long-Term | 464 | 475 |
Deferred Consideration - Long-Term | 2,500 | 2,500 |
Long Term Liability - Other | 14 | 14 |
Total Liabilities | 30,080 | 30,882 |
Stockholders’ Equity: | ||
Preferred Stock, $0.0001 par value, 2,000,000 shares authorized; 15,000 shares issued and outstanding at March 31, 2024 and December 31, 2023 | 0 | 0 |
Common Stock, $0.0001 par value; 170,000,000 shares authorized; 29,556,474 and 29,130,607 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 3 | 3 |
Additional Paid-in Capital | 419,545 | 418,487 |
Accumulated Deficit | (398,929) | (397,198) |
Accumulated Other Comprehensive Income (Loss) | 24 | (1) |
Total Stockholders’ Equity | 20,643 | 21,291 |
Total Liabilities and Stockholders’ Equity | $ 50,723 | $ 52,173 |
 | Dr. Mark Strobeck Ph.D. |
---|---|
 | rockwellmed.com |
 | Pharmaceuticals |
 | 253 |